Kenvue Inc. (NYSE: KVUE), home to household names like Band-Aid, Tylenol, and Neutrogena, is navigating a rough patch. Despite a brand portfolio that spans decades and global reach, the company is struggling to ignite meaningful growth. In 2024, Kenvue’s net sales stood at $15.5 billion, with only a marginal 0.1% increase compared to the previous year. While organic growth was slightly better at 1.5%, foreign exchange headwinds wiped out much of the gain. One of the most concerning signs came from its Skin Health and Beauty segment, which suffered a 4.2% drop in sales—highlighting weak momentum in key areas.
The Cost of Staying Competitive
To combat stagnation, Kenvue is implementing aggressive cost-cutting measures. One of the most notable steps is a workforce reduction of around 4%, with the goal of saving $350 million annually by 2026. These cuts are part of a broader restructuring plan designed to simplify operations and shift focus to high-performing segments. The company is also streamlining its product offerings by eliminating underperforming stock-keeping units (SKUs) and trimming non-core operations. These efforts signal a serious intent to improve margins and unlock efficiency.
Wall Street’s Mixed Signals
Analysts are cautiously optimistic. Kenvue holds a consensus “Moderate Buy” rating, and its average price target sits at $24.36—representing upside potential from its current valuation. However, expectations for 2025 are modest. Adjusted earnings per share are forecasted to grow anywhere from flat to just 2%, indicating limited short-term enthusiasm. The company's strategy may take time to materialize in the form of stronger financial results.
Can Kenvue Break Out of Its Slump?
With a brand portfolio that touches nearly every household, Kenvue has plenty going for it. But heritage alone isn’t enough in today’s dynamic consumer health market. Execution will be everything. Success depends on the company’s ability to trim the fat, double down on innovation, and build stronger consumer connections.
Final Thoughts
Kenvue’s transformation journey is still in the early stages. While there are signs of promise, challenges remain. The next few quarters will be crucial in determining whether this iconic name is poised for a comeback—or destined to tread water. For long-term investors, Kenvue offers a potential value play, but one that requires patience and close attention.